PERSPECTA

News from every angle

← Back to headlines

Barclays Upgrades Phathom Pharmaceuticals to Overweight

Phathom Pharmaceuticals has received an upgrade from Barclays, which raised its rating on the company's stock to Overweight with a new price target of $18, following a recent pullback and optimism surrounding its drug Voquezna.

27 Mar, 15:07 — 27 Mar, 15:07
PostShare

Sources

Showing 1 of 2 sources
YahooMostly Factual21d ago

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Read full article →

Coverage Timeline

First report: Yahoo · 27 Mar, 15:07Full coverage: 2 · 3hWindow: 3h
Left-leaningCenterRight-leaning
Yahoo27 Mar, 15:07First to report

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

3h later
seeking-alpha27 Mar, 17:41Latest update

Phathom upgraded at Barclays following pullback, Voquezna optimism

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

just now

Agusan del Sur to Provide Free Electricity to Low-Income Households

just now

Philippine Lawmaker Cites 2009 EO to Address Fuel Price Hikes

just now

Solar-powered irrigation system installed in Leyte, Philippines

just now